[Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004142
German
Original Title:
Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom und primaer mediastinales großzelliges B-Zell-Lymphom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V (Ablauf Befristung)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/g22-19.html
Year Published:
2022
URL for published report:
https://www.iqwig.de/download/g22-19_axicabtagen-ciloleucel_bewertung-35a-absatz-1-satz-11-sgb-v_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, B-Cell
- Biological Products
- Antineoplastic Agents, Immunological
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
Keywords
- Axicabtagene Ciloleucel
- Lymphoma - Large B-Cell - Diffuse
- Lymphoma - B-Cell
- Health Care Costs
- Epidemiology
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.